Clinical Trial Update: Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial tests an anti-CD38 antibody with a KRAS vaccine and an anti-PD-1 antibody in pancreatic ductal adenocarcinoma and refractory non-small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Anti-CD38 antibody
• Anti-PD-1 antibody
• KRAS vaccine (KRAS-targeted cancer vaccine)

Snippet

Sponsor: Georgetown University | Conditions: Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING